ATXI - AVENUE THERAPEUTICS, INC.
0.42
-0.432 -102.881%
Share volume: 1,156,557
Last Updated: 03-18-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$0.85
-0.43
-0.51%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-15-2024 | 08-11-2023 | 11-13-2023 | 11-14-2024 | 05-15-2024 | 08-09-2024 | 11-14-2024 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 6.429 M | 3.923 M | 2.068 M | 2.120 M | 3.708 M | 2.823 M | 3.156 M | |
| Selling general and admin | 984.000 K | 896.000 K | 1.161 M | 1.138 M | 1.316 M | 1.462 M | 829.000 K | |
| Research and development | 5.445 M | 3.027 M | 907.000 K | 982.000 K | 2.392 M | 1.361 M | 2.327 M | |
| Total expenses | 6.429 M | 3.923 M | 2.068 M | 2.120 M | 3.708 M | 2.823 M | 3.156 M | |
| -38.98% | -47.29% | 2.51% | 74.91% | -23.87% | 11.80% | |||
| Operating income | -6.429 M | -3.923 M | -2.068 M | -2.120 M | -3.708 M | -2.823 M | -3.156 M | |
| Ebit | -7.639 M | -4.073 M | 504.000 K | 926.000 K | -4.398 M | -2.753 M | -3.138 M | |
| Pretax income | -7.602 M | -4.016 M | 513.000 K | 617.000 K | -4.349 M | -2.701 M | -3.087 M | |
| -47.17% | -112.77% | 20.27% | -804.86% | -37.89% | 14.29% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -7.602 M | -4.016 M | 513.000 K | 617.000 K | -4.349 M | -2.701 M | -3.087 M | |
| 47.17% | 112.77% | 20.27% | -804.86% | 37.89% | -14.29% |
